Advances in miRNA Research in Hepatocellular Carcinoma  

作　　者：Erqi Li Bin Zheng Jian Li 

机构地区：[1]Affiliated Hospital of Chengde Medical College,Chengde,Hebei,067000,China

出　　处：《Journal of Advances in Medicine Science》2024年第1期1-6,共6页医学科学进展杂志（英文）

摘　　要：Globally,Hepatocellular carcinoma(HCC)is recognized as a major malignant tumor,being the 6th most common in terms of occurrence and ranking third in mortality rates among all cancer types.Within China,HCC is noted as the fourth most prevalent cancer and the second most common cause of cancer-related fatalities.The difficulty in managing HCC stems from its tendency to remain undetected due to a lack of symptoms in the early stages,along with the current lack of both effective diagnostic techniques and treatments for chemotherapy.MiRNA,also referred to as microRNA,is a type of non-coding RNA typically consisting of 19-22 nucleotides in length.Upon binding to the mRNA of target genes,it functions to suppress mRNA translation or induce mRNA degradation,thereby exerting regulatory control over gene expression.Recent research increasingly suggests the pivotal involvement of miRNA in the onset and progression of primary hepatic cells.Studies exploring the association between miRNA and primary hepatic cell carcinoma hold substantial clinical significance in elucidating the pathogenesis,facilitating diagnosis,and advancing treatment modalities for liver cancer.

关 键 词：Hepatocellular carcinoma MIRNA 

分 类 号：R73[医药卫生—肿瘤]